Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | DDO | Q99489 | 1/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30114776 | 1.00 | DAO (0.60) | DAOBRD4DDOAOC3KDR | |
| Benzimidazole SCHEMBL27731337 | 0.83 | KDR (0.47) | DAOBRD4DDOAOC3KDR | |
| SCHEMBL1270149 | 0.76 | CYP1A2 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7339379 | 0.76 | PARP1 (0.57) | BRD4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL248620 | 0.75 | BRD4 (1.00) | DAOBRD4DDOAOC3KDR | |
| SCHEMBL1582138 | 0.75 | DAO (0.60) | DAOBRD4DDOAOC3KDR | |
| SCHEMBL6283609 | 0.75 | DAO (0.60) | DAOBRD4DDOAOC3KDR | |
| SCHEMBL10617 | 0.75 | DAO (0.60) | DAOBRD4DDOAOC3KDR | |
| SCHEMBL1394237 | 0.75 | DAO (0.60) | DAOBRD4DDOAOC3KDR | |
| SCHEMBL10285239 | 0.75 | DAO (0.60) | DAOBRD4DDOAOC3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515612-A | Amine vinyl quinolone compound and preparation method and application thereof | 西南大学 | 2024-08-20 | — | — | CN | claimed |
| EP-2234979-B1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, process for their production and their use as anti-inflammatory agents | BAYER IP GMBH (DE) | 2016-05-25 | — | — | EP | claimed |
| CN-101868448-B | 5- [ (3,3, 3-trifluoro-2-hydroxy-1-arylpropyl) amino ] -1H-quinolin-2-ones, process for their preparation and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AG | 2013-06-12 | — | — | CN | claimed |
| US-8110404-B2 | Luminescent lanthanide binding chelates | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-07 | — | — | US | claimed |
| CN-101868448-A | 5- [ (3,3, 3-trifluoro-2-hydroxy-1-arylpropyl) amino ] -1H-quinolin-2-ones, process for their preparation and their use as anti-inflammatory agents | ASTRAZENECA AB | 2010-10-20 | — | — | CN | claimed |
| EP-2234979-A1 | 5-Ý(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO¨-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | claimed |
| EP-2149558-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-03 | — | — | EP | claimed |
| WO-2010009814-A1 | 5-[ (3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL) AMINO]-1-ARYLQUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | WO | claimed |
| US-20100016338-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-21 | — | — | US | claimed |
| EP-2072509-A1 | 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-24 | — | — | EP | claimed |
| WO-2009065503-A1 | 5-[(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO]-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-28 | — | — | WO | claimed |
| US-20090137564-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A Process for Their Production and Their Use as Anti-inflammatory Agents | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | claimed |
| EP-2062880-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-27 | — | — | EP | claimed |
| US-20080299675-A1 | Luminescent Lanthanide Binding Chelates | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2008-12-04 | — | — | US | claimed |
| WO-2007055700-A1 | LUMINESCENT LANTHANIDE BINDING CHELATES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-05-18 | — | — | WO | claimed |
| CN-1874795-A | Method for coating implants by way of a printing method | BLUE MEMBRANES GMBH (DE) | 2006-12-06 | — | — | CN | claimed |
| CN-1791437-A | Medical implants comprising biocompatible coatings | BLUE MEMBRANES GMBH (DE) | 2006-06-21 | — | — | CN | claimed |
| CN-1086515-A | Aminoquinolone derivative and anti-hiv agent that aryl or fragrant heterocyclic radical replace | UBE INDUSTRIES (JP) | 1994-05-11 | — | — | CN | claimed |
| JP-7002782-A | — | — | None | — | — | JP | disclosed |
| US-3968119-A | OPTICAL BRIGHTENERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016338-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents | PTGES, PTGES2, PTGS1 | DAO 825/4885BRD4 684/4885DDO 1110/4885 |
| US-20080299675-A1 | Luminescent Lanthanide Binding Chelates | HLCS, LYAR, SLC6A13 | DAO 2847/4885BRD4 643/4885DDO 1923/4885 |
| US-20090137564-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A Process for Their Production and Their Use as Anti-inflammatory Agents | IL1B, PTGES2, PTGES | DAO 696/4885BRD4 836/4885DDO 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.